C4 Therapeutics, Inc.

C4 Therapeutics, Inc.

C4 Therapeutics, Inc.

Overview
Date Founded

2015

Headquarters

490 Arsenal Way, Suite 200, Watertown, MA, 02472, USA

Type of Company

Public

Employees (Worldwide)

88

Industries

Biotechnology
Pharmaceuticals
IT Consulting & Services
Medical Support Services

Company Description

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at C4 Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder, Executive Chairman

President & Chief Executive Officer

Treasurer, Chief Financial & Accounting Officer

Chief Scientific Officer

Chief Medical Officer

Chief People Officer

Secretary & Chief Legal Officer

Senior Vice President, Communications & Investor Relations

Senior Vice President, Biological Sciences

Senior Vice President, Chemistry

Paths to C4 Therapeutics, Inc.
Potential Connections via
Relationship Science
You
C4 Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $7.3 billion across our strategies.

Details Hidden

RTW Investments aims to generate attractive risk-adjusted returns through investments in securities, both equity and debt, long and short, of companies with a focus on the healthcare sector. The Funds will primarily invest in the equity and debt of public and private issuers globally, with a focus on the US and Europe. Derivatives are employed to improve payoff structures, as well as to construct hedges.

Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Recent Transactions
Details Hidden

C4 Therapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Advisors & Consultants
Consultant

Chief Executive Officer at MBJC Associates LLC

Consultant

Former Chief Accounting Officer, Vice President-Finance & Controller at C4 Therapeutics, Inc.

Clients

Alphabet, Inc. is a holding company, which engages in the business of acquisition and operation of different companies. It operates through the Google and Other Bets segments. The Google segment includes its main Internet products such as ads, Android, Chrome, hardware, Google Cloud, Google Maps, Google Play, Search, and YouTube. The Other Bets segment consists of businesses such as Access, Calico, CapitalG, GV, Verily, Waymo, and X. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

Key Stats and Financials As of 2020
Market Capitalization
$2.01B
Total Enterprise Value
$1.08B
Earnings Per Share
$-1.54
Revenue
$33.2M
Net Profit
$-66.3M
EBITDA
$-57.6M
EBITDAMargin
-173.54%
Total Debt
$22.9M
Total Equity
$281M
Enterprise Value / Sales
32.47x
TEVNet Income
-16.25x
Debt TEV
0.02x
Investors
Details Hidden

Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $7.3 billion across our strategies.

Details Hidden

Bain Capital Life Sciences invests in companies located around the world. The firm focuses on sectors such as biopharmaceutical, specialty pharmaceuticals, medical devices, diagnostics, and life science technology. The firm participates in growth capital transactions.

Details Hidden

EG Capital Group focuses on buy-outs of and providing growth capital for small- and medium-sized companies with strong management in attractive industries in the US and Canada. The firm targets established and profitable businesses, primarily in the consumer products sector, including food, beverage, personal care and household products, retail and restaurants. The firm may also invest in the media sector

Competitors
AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by C4 Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of C4 Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and C4 Therapeutics, Inc..